Cochrane · systematic review · CD007654
Long‐term effects of weight‐reducing drugs in people with hypertension
Siebenhofer, A, Winterholer, S, Jeitler, K, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
21
current version
GRADE rated
21
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 3 · 14.3%Low 9 · 42.9%Moderate 9 · 42.9%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyOrlistat versus placebo for weight reduction
Population: Men and non‐pregnant women ≥ 18 years old with essential hypertension
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Total mortality Orlistat vs placebo | no estimate extracted | 3 studies · 1488 participants | Low Downgraded: imprecision |
Cardiovascular morbidity Orlistat vs placebo | no estimate extracted | 3 studies · 1811 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events Orlistat vs placebo | RR 1.45 [1.1, 1.91] | 3 studies · 1476 participants | Moderate Downgraded: imprecision |
All adverse events Orlistat vs placebo | RR 1.13 [0.84, 1.54] | 2 studies · 1386 participants | Very low Downgraded: imprecision, inconsistency |
Change in systolic blood pressure compared to placebo (mm Hg) from baseline to end of study Orlistat vs placebo | no estimate extracted | 4 studies · 2058 participants | Moderate Downgraded: imprecision |
Change in diastolic blood pressure compared to placebo (mm Hg) from baseline to end of study Orlistat vs placebo | no estimate extracted | 4 studies · 2058 participants | Moderate Downgraded: imprecision |
Change in body weight compared to placebo (kg) from baseline to end of study Orlistat vs placebo | no estimate extracted | 4 studies · 2080 participants | Low Downgraded: imprecision, inconsistency |
Phentermine/topiramate versus placebo for weight reduction
Population: Men and non‐pregnant women ≥ 18 years old with essential hypertension
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Total mortality Phentermine/topiramate vs placebo | no estimate extracted | 1 study · 1305 participants | Low Downgraded: imprecision |
Cardiovascular morbidity Phentermine/topiramate vs placebo | no estimate extracted | 1 study · 1305 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events Phentermine/topiramate vs placebo | RR 0.85 [0.49, 1.48] | 1 study · 1305 participants | Low Downgraded: imprecision |
All adverse events Phentermine/topiramate vs placebo | RR 1.13 [1.08, 1.2] | 1 study · 1305 participants | Low Downgraded: imprecision |
Change in systolic blood pressure compared to placebo (mm Hg) from baseline to end of study Phentermine/topiramate vs placebo | no estimate extracted | 1 study · 772 participants | Low Downgraded: imprecision |
Change in diastolic blood pressure compared to placebo (mm Hg) from baseline to end of study Phentermine/topiramate vs placebo | no estimate extracted | 1 study · 772 participants | Low Downgraded: imprecision |
Change in body weight as compared to placebo (%) from baseline to end of study Phentermine/topiramate vs placebo | no estimate extracted | 1 study · 772 participants | Low Downgraded: imprecision |
Naltrexone/bupropion versus placebo for weight reduction
Population: Men and non‐pregnant women ≥ 18 years old with essential hypertension
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Total mortality Naltrexone/bupropion vs placebo | RR 0.99 [0.7, 1.4] | 1 study · 8283 participants | Moderate Downgraded: imprecision |
Cardiovascular morbidity Naltrexone/bupropion vs placebo | RR 1.11 [0.87, 1.41] | 1 study · 8283 participants | Low Downgraded: risk of bias, imprecision |
Serious adverse events Naltrexone/bupropion vs placebo | RR 1.05 [0.96, 1.14] | 1 study · 8283 participants | Moderate Downgraded: imprecision |
All adverse events Naltrexone/bupropion vs placebo | RR 1.69 [1.58, 1.8] | 1 study · 8283 participants | Moderate Downgraded: imprecision |
Change in systolic blood pressure as compared to placebo (mm Hg) from baseline to end of study Naltrexone/bupropion vs placebo | no estimate extracted | 1 study · 8283 participants | Moderate Downgraded: imprecision |
Change in diastolic blood pressure as compared to placebo (mm Hg) from baseline to end of study Naltrexone/bupropion vs placebo | no estimate extracted | 1 study · 8283 participants | Moderate Downgraded: imprecision |
Change in body weight as compared to placebo (kg) from baseline to end of study Naltrexone/bupropion vs placebo | no estimate extracted | 1 study · 8283 participants | Moderate Downgraded: imprecision |
Summary of findings for orlistat versus placebo
Population: Men and non‐pregnant women ≥ 18 years old with essential hypertension
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in systolic blood pressure as compared to placebo [mm Hg] from baseline to end of study Summary of findings for orlistat vs placebo | no estimate extracted | 4 studies · 2058 participants | Low Downgraded: risk of bias |
Change in diastolic blood pressure as compared to placebo [mm Hg] from baseline to end of study Summary of findings for orlistat vs placebo | no estimate extracted | 4 studies · 2058 participants | Low Downgraded: risk of bias |
Change in body weight as compared to placebo [kg] from baseline to end of study Summary of findings for orlistat vs placebo | no estimate extracted | 4 studies · 2080 participants | Moderate Downgraded: risk of bias |
Summary of findings for sibutramine versus placebo
Population: Men and non‐pregnant women ≥ 18 years old with essential hypertension
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in systolic blood pressure as compared to placebo [mm Hg] from baseline to end of study Summary of findings for sibutramine vs placebo | no estimate extracted | NR | No studies |
Change in diastolic blood pressure as compared to placebo [mm Hg] from baseline to end of study Summary of findings for sibutramine vs placebo | no estimate extracted | 2 studies · 428 participants | Low Downgraded: risk of bias |
Change in body weight as compared to placebo [kg] from baseline to end of study Summary of findings for sibutramine vs placebo | no estimate extracted | 4 studies · 574 participants | Low Downgraded: risk of bias |